Vedolizumab specifically recognizes the 47 integrin and selectively blocks gut lymphocyte trafficking: potentially, it offers gut-specific immunosuppression.
To review the safety of vedolizumab and summarise post-marketing data to assess if any safety concerns that differ from registration trials have emerged.
A systematic bibliographic search identified six registration trials and nine cohort studies.
- Publication status:
- Peer review status:
- Peer reviewed
- Accepted manuscript
- Wiley Publisher's website
- Alimentary Pharmacology and Therapy Journal website
- Publication date:
- Acceptance date:
- Pubs id:
- Local pid:
- Copyright holder:
- John Wiley and Sons Ltd
- Copyright date:
- © 2017 John Wiley and Sons Ltd. This is the accepted manuscript version of the article. The final version is available online from Wiley at: http://dx.doi.org/10.1111/apt.14075
Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
If you are the owner of this record, you can report an update to it here: Report update to this record